COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,384 Articles (22,816 medRxiv, 8,568 bioRxiv)

Most recent first Previous |  Page 1152: Articles 11511-11520  | Next

Waning, Boosting and a Path to Endemicity for SARS-CoV-2.
Keeling, M. J., Thomas, A. C., Hill, E. M., Thompson, R. N., Dyson, L. N., Tildesley, M., Moore, S.
10.1101/2021.11.05.21265977 — Posted: 2021-11-09
Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease
Davenport, B. J., Catala, A., Weston, S. M., Johnson, R. M., Ardunay, J., Hammond, H. L., Dillen, C., Frieman, M. B., Catalano, C. E., Morrison, T. E.
10.1101/2021.11.08.467648 — Posted: 2021-11-09
A mathematical model for repetitive behaviors of Covid-19
Nishimoto, Y., Inoue, K.
10.1101/2021.11.08.21266099 — Posted: 2021-11-09
Neutralisation of SARS-CoV-2 Delta sub-lineage AY.4.2 and B.1.617.2+E484K by BNT162b2 mRNA vaccine-elicited sera
Lassauniere, R., Polacek, C., Fonager, J., Bennedbaek, M., Boding, L., Rasmussen, M., Fomsgaard, A.
10.1101/2021.11.08.21266075 — Posted: 2021-11-09
Data-driven prognosis for COVID-19 patients based on symptoms and age
Paul, S., Lorin, E.
10.1101/2021.11.08.21266091 — Posted: 2021-11-09
Cumulative incidence of SARS-CoV-2 and associated risk factors among healthcare workers in the Eastern Cape, South Africa
Stead, D. F., Adeniyi, O. V., Singata-Madliki, M., Abrahams, S., Batting, J., Jelliman, E., Parrish, A. G.
10.1101/2021.11.08.21265966 — Posted: 2021-11-09
Ad26.COV2.S breakthrough infections induce high titers of antibodies capable of neutralizing variants of concern
Kitchin, D., Richardson, S. I., van der Mescht, M. A., Motlou, T., Mzindle, N., Moyo-Gwete, T., Makhado, Z., Ayres, F., Manamela, N. P., Spencer, H., Lambson, B., Oosthuysen, B., Mennen, M., Skelem, S., Williams, N., Ntusi, N. A. B., Burgers, W. A., Gray, G. G., Bekker, L.-G., Boswell, M. T., Rossouw, T. M., Ueckermann, V., Moore, P. L.
10.1101/2021.11.08.21266049 — Posted: 2021-11-09
Understanding COVID-19 trajectories from a nationwide linked electronic health record cohort of 56 million people: phenotypes, severity, waves & vaccination
Thygesen, J. H., Tomlinson, C. R., Hollings, S., Mizani, M. A., Handy, A., Akbari, A., Banerjee, A., Cooper, J. A., Lai, A. G., Li, K., Mateen, B. A., Sattar, N., Sofat, R., Torralbo, A., Wu, H., Wood, A., Sterne, J. A., Pagel, C., Whiteley, W., Sudlow, C., Hemingway, H., Denaxas, S., CVD-COVID-UK Consortium
10.1101/2021.11.08.21265312 — Posted: 2021-11-09
Vaccine effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca to prevent severe COVID-19 in Costa Rica by September and October 2021: A nationwide, observational study of hospitalisations prevalence.
Rosero-Bixby, L.
10.1101/2021.11.08.21266087 — Posted: 2021-11-09
Time varying association between deprivation, ethnicity and SARS-CoV-2 infections in England: a space-time study
Padellini, T., Jersakova, R., Diggle, P. J., Holmes, C., King, R., Lehmann, B., Mallon, A.-M., Nicholson, G., Richardson, S., Blangiardo, M.
10.1101/2021.11.09.21266054 — Posted: 2021-11-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).